Cognition Therapeutics announced that the company has reached target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER study, which is examining the safety and effectiveness of CT1812 in adults with mild-to-moderate dementia with Lewy bodies. Top-line results are expected in the second half of 2024 after the last participants have completed six months of treatment. “There are currently no approved disease-modifying therapies for DLB, leaving people living with this disease in desperate need of treatment options,” Lisa Ricciardi, president and CEO of Cognition Therapeutics, stated, “The majority of patients with DLB have both Abeta and alpha-synuclein pathology. Because of our unique mechanism of action that targets both Abeta and alpha-synuclein oligomers, we believe that CT1812 may be able to slow the progression of disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
- Cognition Therapeutics provided recap of virtual KOL event
- Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
- Cognition Therapeutics to hold a conference call
- Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference